Filed: July 24, 2019

Filed on behalf of: Eli Lilly and Company

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ELI LILLY AND COMPANY Petitioner

v.

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Patent Owner

Case IPR2018-01422 (Patent No. 9,340,614)

Case IPR2018-01423 (Patent No. 9,266,951)

Case IPR2018-01424 (Patent No. 9,346,881)

Case IPR2018-01425 (Patent No. 9,890,210)

Case IPR2018-01426 (Patent No. 9,890,211)

Case IPR2018-01427 (Patent No. 8,597,649)¹

PETITIONER'S NOTICE OF DEPOSITION OF DR. ALAN M. RAPOPORT

The word-for-word identical paper is filed in each proceeding identified in the caption.



IPR2018-01422, -01423, -01424, -01425, -01426, -01427

Pursuant to 37 C.F.R. § 42.53(d)(4), Petitioner Eli Lilly and Company hereby provides notice that it will cross-examine Dr. Alan M. Rapoport, a witness of Patent Owner Teva Pharmaceuticals International GMBH. Pursuant to the agreement of counsel, the deposition will take place on Thursday, August 22, 2019, beginning at 9:00 am at Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, DC 20005.

The deposition will take place before a Notary Public or other officer authorized by law to administer oaths, and will be recorded using stenographic means.

Respectfully submitted,

Date: July 24, 2019 By: ___/ Pier D. DeRoo /

Pier D. DeRoo (Reg. No. 69,340)



CERTIFICATE OF SERVICE

The undersigned certifies that a copy of the foregoing Petitioner's Notice of

Deposition of Dr. Alan M. Rapoport was served electronically via email on July

24, 2019, in its entirety on the following:

Deborah A. Sterling
Robert C. Millonig
Gaby L. Longsworth
Jeremiah B. Frueauf
Olga A. Partington
Dennies Varughese
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, NW
Washington, DC 20005
dsterling-PTAB@sternekessler.com
bobm-PTAB@sternekessler.com
glongs-PTAB@sternekessler.com
jfrueauf-PTAB@sternekessler.com
opartington-PTAB@sternekessler.com
dvarughe-PTAB@sternekessler.com

Patent Owner has consented to service by email.

Date: July 24, 2019 By: / William Esper /

William Esper

Litigation Legal Assistant

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP

